Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN-Reference-Cited by-同舟云学术

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Published:2022-04 Issue:2 Volume:7 Page:100408
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Paz-Ares L.^ORCID,Chen Y.,Reinmuth N.,Hotta K.,Trukhin D.,Statsenko G.,Hochmair M.J.,Özgüroğlu M.,Ji J.H.,Garassino M.C.,Voitko O.,Poltoratskiy A.,Musso E.,Havel L.,Bondarenko I.,Losonczy G.,Conev N.,Mann H.,Dalvi T.B.,Jiang H.,Goldman J.W.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference15 articles.

1. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019

2. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018

3. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study;Garon;J Clin Oncol,2019

4. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer;Borghaei;J Clin Oncol,2021

5. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Spigel;J Clin Oncol,2022

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy;International Immunopharmacology;2024-11

2. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China;International Journal of Clinical Pharmacy;2024-09-14

3. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer;New England Journal of Medicine;2024-09-13

4. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

5. Proceedings of the 1st biannual bridging the gaps in lung cancer conference;The Oncologist;2024-09-05